Publication | Open Access
Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
104
Citations
0
References
2001
Year
Phase IiiPharmacologyImmunologyHepatitisAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapySafety ResultsInterferon Alfa-2aAntiviral DrugMedicineNovel Therapy
No additional data available for this publication yet. Check back later!